- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01332955
Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen (TelapreVIH)
Pilot Study of PegInterferon-Ribavirin-Telaprevir Efficacy and Tolerability in HIV-HCV Coinfected Patients Who Had Previously Failed a PegInterferon-Ribavirin Regimen. (ANRS HC26 TelapreVIH)
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This phase II pilot trial is designed for HIV-1 and HCV genotype 1 coinfected patients who had previously failed a peginterferon-ribavirin regimen.
Intervention Design:
- Induction, Lead-in, phase: day 0 to week 4 PegInterferon alpha-2a, 180 µg subcutaneous injection, once weekly + Ribavirin (weight-based dose) 1000 mg for subjects weighing <75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d.
Telaprevir phase: week 4 to week 16 PegInterferon alpha-2a, 180 µg subcutaneous injection, once weekly + Ribavirin (weight-based dose) 1000 mg for subjects weighing <75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d.
+ Telaprevir 750 mg q 8h (or 1125 mg q 8h in association with Efavirenz)
- Maintenance phase: week 16 to week 48 or 72 PegInterferon alpha-2a, 180 µg subcutaneous injection, once weekly + Ribavirin (weight-based dose) 1000 mg for subjects weighing <75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d.
The duration of the maintenance phase is determined by the RVR at week 8 (4 weeks after Telaprevir start.
Complete RVR (not measurable HCV-RNA at week 8): maintenance from week 16 to week 48
_Partial RVR (HCV-RNA below 1 000 UI/mL but still measurable at week 8): maintenance phase from week 16 to week 48
And stable antiretroviral treatment for over 3 months among the authorized combinations: (tenofovir 300 mg, emtricitabine 200 mg, atazanavir 300 mg, ritonavir 100 mg) q.d. or (tenofovir 300 mg, emtricitabine 200 mg, efavirenz 600 mg) q.d. or (tenofovir 300 mg, emtricitabine 200 mg q.d. and raltegravir 400 mg b.i.d.) once Drug-Drug interaction data will be available. Patients who could not receive one of these 3 combinations can be included if they are receiving a stable combination of at least 3 drugs among the following: tenofovir, emtricitabine/lamivudine, efavirenz, atazanavir-boosted or not, raltegravir (once Drug-Drug interaction data will be available). These patients cannot participate in the pharmacokinetic study.
The trial will enroll 80 subjects. The proportion of patients included, presenting with cirrhosis (METAVIR F4) will remain below 50% of all patients The proportion of patients included, null-responders to previous HCV treatment (HCV-RNA decline at week 12 less than 2 log10 UI/ml) but no cirrhosis (maximum equal METAVIR F3) will remain below 30% of patients.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Lyon, Frankrig
- Service Maladies Infectieuses et Tropicales, Hôpital de la Croix-Rousse
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Informed consent form signed at screening visit at the latest
- Patient registered with or covered by a social security scheme
- HIV-1 infection
- Chronic, genotype 1, hepatitis C with detectable HCV RNA at screening
- Virological failure following a previous treatment of at least 12 weeks by peginterferon alpha-2a ≥ 135 µg once weekly or peginterferon alpha-2b ≥ 1.0 µg per kg once weekly + ribavirin ≥ 600 mg once daily. Virological failure defined by persistence of a detectable HCV-RNA, with the same genotype than before. Null responder patient, with less than 2 Log10 HCV-RNA decline at week 12 with cirrhosis are excluded from the study. Null responder patients without cirrhosis (equal or below METAVIR F3) are limited to less than 30 % of all patients included
- No Interferon and/or Ribavirin within past 6 months
- Stable antiretroviral treatment for over 3 months at screening. Authorized combinations: tenofovir-emtricitabine-boosted atazanavir,tenofovir-emtricitabine-efavirenz,tenofovir-emtricitabine-raltegravir, once Drug-Drug interaction data will be available. Patients with a stable combination of at least 3 of the following drugs: tenofovir, emtricitabine/lamivudine, efavirenz, atazanavir-boosted or not, raltegravir. These patients cannot participate in the pharmacokinetic study
- CD4 >200/mm3 and >15% at screening
- Plasma HIV-RNA <50 copies/mL for at least 6 months at screening visit
- Body weight ≥ 40 kg to equal or below 125 kg
- Fibrosis stage have to be documented by a significant liver biopsy (cumulative length ≥ 15 mm or ≥ 6 portal spaces), within 3 years. Patients with a previous liver biopsy exhibiting cirrhosis lesions (METAVIR F4) are allowed to enter the study without a new biopsy. The proportion of patients with cirrhosis lesions (METAVIR F4) is limited to 50% of all patients.
- Male patients, female patients with child-bearing potency and their heterosexual partners must use an adequate contraception from 1 month before initiation of treatment to 7 months following the end of treatment for men and to 4 months following the end of treatment for women. Subjects (or their female partners) must not be pregnant or planning to become pregnant within 2 years after enrolling in the study
Exclusion Criteria:
- Patient with liver failure (Child B and C) or past history of decompensated cirrhosis
- Significant oesophageal varices (Stages 2-3) on a gastrointestinal endoscopy within 3 years
- Detectable AgHBs
- HIV-2 co-infection
- Contra-indication to ribavirin or peginterferon
- Severe pre-existing cardiac or pulmonary disease
- Untreated dysthyroidism
- Uncontrolled Type 2 diabetes
- Optic neuritis past history and retinal condition
- History of organ transplant
- Severe hemoglobinopathy
- Congenital QT prolongation, family history of congenital QT prolongation or sudden unexpected death
- Contra-indication to telaprevir, hypersensitivity to any component of the drug product
- Any disease requiring long term, systemic corticotherapy or immunosuppressive therapy during study
- Alcohol intake that may represent an obstacle for the participation of the subject
- Substance abuse that may represent an obstacle for the participation of the subject
- Acute CDC stage C opportunistic infection within the previous 6 months
- Past history of cancer within the previous 5 years (except skin basal cell carcinoma, Kaposi's disease in stable remission, in situ cervical cancer and in situ anal cancer)
- Any active malignant disease including hepatocellular carcinoma
- Patients unable to observe the study procedures
- Participation to another clinical trial within the previous 30 days
- Haemoglobin <120 g/L for women and <130 g/L for men
- Platelets <90 000/mm3
- Neutrophils <1 500/mm3
- Renal insufficiency defined by an estimated Glomerular Filtration Rate < 60 mL/mn (MDRD equation)
- Associated medication susceptible to interfere with the pharmacokinetic parameters of telaprevir and/or antiretroviral associated drugs
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Telaprevir-pegIFN alfa-2a-ribavirine
Single Group Assignment
|
Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz
Andre navne:
Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks
Andre navne:
(weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Estimation of SVR following a 12 wks treatment by telaprevir combined with a 48 or 72 wks peginterferon-ribavirin treatment, based upon the rapid virological response, and comparison to 20% (which would correspond to a significant therapeutic benefit)
Tidsramme: up to 92 weeks or 116 weeks depending on rapid virologic response
|
HCV-RNA measured 24 weeks after the end of HCV treatment
|
up to 92 weeks or 116 weeks depending on rapid virologic response
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Tidsramme: From week 0 up to 92 weeks or 116 weeks depending on rapid virologic response
|
From week 0 up to 92 weeks or 116 weeks depending on rapid virologic response
|
|
Estimation of the Sustained Virological Response defined as undetectable HCV-RNA at Week 12 after the end of HCV treatment
Tidsramme: at Week 60 or Week 84 depending on rapid virologic response
|
HCV-RNA measured 12 weeks after the end of HCV treatment
|
at Week 60 or Week 84 depending on rapid virologic response
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Laurent COTTE, MD, Hopital Croix Rousse LYON FRANCE
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Seksuelt overførte sygdomme, virale
- Seksuelt overførte sygdomme
- Lentivirus infektioner
- Retroviridae infektioner
- Immunologiske mangelsyndromer
- Sygdomme i immunsystemet
- Leversygdomme
- Flaviviridae infektioner
- Hepatitis, viral, menneskelig
- Hepatitis, kronisk
- HIV-infektioner
- Hepatitis
- Hepatitis C
- Hepatitis C, kronisk
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Antimetabolitter
- Ribavirin
- Peginterferon alfa-2a
Andre undersøgelses-id-numre
- 2010-023287-41
- ANRS HC26 TelapreVIH (Anden identifikator: (Inserm-ANRS))
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med HIV-infektion
-
University of Santiago de CompostelaOsteology FoundationRekruttering
-
Institut PasteurRekruttering
-
Universidad del DesarrolloAfsluttetHealthcare Associated InfectionChile
-
The University of Texas Health Science Center,...EurofinsAfsluttetOdontogen Deep Space Neck InfectionForenede Stater
-
Imelda Hospital, BonheidenAfsluttetHealthcare Associated InfectionBelgien
-
Centre Hospitalier Universitaire de NīmesRekrutteringÆldre | Healthcare Associated InfectionFrankrig
-
Centre Hospitalier Universitaire, AmiensAfsluttetHealthcare Associated Infection | IglerFrankrig
-
University of PennsylvaniaAfsluttetAntimikrobiel resistensForenede Stater, Botswana
-
University of Maryland, BaltimoreVA Office of Research and DevelopmentAfsluttetMenneskelig mikrobiomForenede Stater
-
Universidad Autonoma de Nuevo LeonUkendtSundhedsrelaterede infektioner
Kliniske forsøg med Telaprevir
-
Vertex Pharmaceuticals IncorporatedTibotec Pharmaceutical LimitedAfsluttetHepatitis CForenede Stater, Frankrig, Canada, Tyskland, Puerto Rico
-
Tibotec BVBAAfsluttet
-
Janssen Infectious Diseases BVBAAfsluttetNedsat leverfunktionTyskland, Tjekkiet
-
Vertex Pharmaceuticals IncorporatedAfsluttetHepatitis CNew Zealand
-
Mitsubishi Tanabe Pharma CorporationVertex Pharmaceuticals IncorporatedAfsluttet
-
Santaris Pharma A/SAfsluttetHepatitis C | Kronisk hepatitis CForenede Stater
-
GlaxoSmithKlineAfsluttet
-
Massachusetts General HospitalTrukket tilbageViral hepatitis CForenede Stater
-
Mitsubishi Tanabe Pharma CorporationVertex Pharmaceuticals IncorporatedAfsluttetKronisk hepatitis CJapan
-
MassBiologicsAfsluttet